Hikma signs multi-year exclusive licensing and distribution agreement with Dr. Reddy’s for Nicotinell across MENA

MENA-region scope; no African country is named in the release coverage reviewed, so the African nexus is regional and flagged.


Coverage: The Meridian legal market record (editorial).

MENA-region scope; no African country is named in the release coverage reviewed, so the African nexus is regional and flagged.

Record ID TX-AFR-2026-0025
Record type Commercial IP transaction
Transaction type Trade mark licence, Exclusive licence, In-licensing
IP rights trade mark, regulatory data
Status Signed
Qualifying date 2026-09-28
Sector Life sciences · Pharmaceuticals – consumer health
African markets Multi-jurisdictional
Licensed territory MENA region.
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, single · 1 source(s)
Last verified 2026-10-25

Parties

  • Hikma Pharmaceuticals International Limited (United Kingdom): licensee
  • Dr. Reddy's Laboratories SA (India): licensor

Key terms

  • Interest: exclusive licence; Exclusivity: exclusive; Territorial scope: MENA region; Term: Multi-year (no term length stated)

Sources

  1. Hikma signs exclusive licensing and distribution agreement with Dr. Reddy's Laboratories for Nicotinell across MENA, Zawya (press release), 2026-09-28

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.